SPK-8011QQ

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemophilia A

Conditions

Hemophilia A

Trial Timeline

Mar 31, 2026 → Jul 31, 2031

About SPK-8011QQ

SPK-8011QQ is a phase 1/2 stage product being developed by Roche for Hemophilia A. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07226206. Target conditions include Hemophilia A.

What happened to similar drugs?

20 of 20 similar drugs in Hemophilia A were approved

Approved (20) Terminated (3) Active (0)
EmicizumabRocheApproved
BenefixPfizerApproved
Nonacog alfaPfizerApproved
Moroctocog alfa(AF-CC)PfizerApproved
Factor IX recoveryPfizerApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07226206Phase 1/2Recruiting

Competing Products

20 competing products in Hemophilia A

See all competitors
ProductCompanyStageHype Score
EmicizumabChugai PharmaceuticalPhase 3
40
EmicizumabChugai PharmaceuticalPhase 3
40
Emicizumab + rFVIIa + aPCCChugai PharmaceuticalPhase 3
40
Human Coagulation Factor VIIIChugai PharmaceuticalPhase 3
47
EmicizumabChugai PharmaceuticalPhase 3
47
Emicizumab + Factor VIII (FVIII)Chugai PharmaceuticalPhase 3
40
EmicizumabRochePhase 3
40
HEMLIBRAJohnson & JohnsonPre-clinical
26
EmicizumabRochePhase 3
40
EmicizumabRocheApproved
47
EmicizumabRochePhase 3
44
NXT007RochePhase 1/2
39
Emicizumab InjectionRochePhase 2
35
Bypassing Agents + FVIII ReplacementRochePre-clinical
26
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086PfizerPhase 2
35
Nonacog Alfa (Genetical Recombination)PfizerPre-clinical
26
Refacto AFPfizerPre-clinical
18
PF-06838435/ fidanacogene elaparvovecPfizerPhase 3
44
ReFacto AFPfizerPhase 3
40
Nonacog alfa + Nonacog alfaPfizerPhase 3
40